Cervical Cancer
1,296
238
319
529
Key Insights
Highlights
Success Rate
86% trial completion
Published Results
124 trials with published results (10%)
Research Maturity
529 completed trials (41% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
6.6%
85 terminated out of 1296 trials
86.2%
-0.4% vs benchmark
10%
128 trials in Phase 3/4
23%
124 of 529 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 529 completed trials
Clinical Trials (1296)
Improving Diagnostics in Cervical Dysplasia
Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India
Cervical Cancer Prevention for Black Adults
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Comprehensive Evaluation of Tumor Oxygenation, Metabolism and Blood Supply of High Grade Glioma and Cervical Cancers Using Dynamic FAZA PET and Multiparametric MR
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
Feasibility of HPV Self-Collection Kits for Cervical Cancer Screening
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Identifying and Addressing Barriers to Retention in the Cervical Cancer Treatment Cascade Among Women With HIV in South Africa: Part 2
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
DESTINY-PANTUMOUR04
Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors